Case Studies of Pharmaceutical Megabrands
This 38-page document includes 16 case studies on the success of various pharmaceutical products that have been launched in the last few years. Learn the marketing profiles, tactics and strategies that made these products into blockbusters. Products studied include Lipitor, Allegra, Botox and Cipro. This research originated from Best Practices, LLC's consulting services.
Sales and Marketing > New Product Development and Launch > Planning and Coordinating Launch > Launch Strategy and Structure
Industries Profiled:
Pharmaceutical; Health Care; Consumer Products; Diagnostic; Biotech
Companies Profiled:
GlaxoSmithKline ; Sanofi-aventis; Eli Lilly; Ortho Biotech; Bristol-Myers Squibb; AstraZeneca; Schering-Plough; Wyeth; Bayer; Merck; Pharmacia; Allergan; Pfizer
Special Offer: If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call Benjamin Gregory at 919-767-9160 if you have any questions.
Other Research in:
Sales and Marketing > New Product Development and Launch > Planning and Coordinating Launch > Launch Strategy and Structure
Select items of interest and click the "Add Selected Items to Cart" button below.
 | Pitfalls to Avoid for a Strong Oncology Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls
|
Non-members: Click here to review a complimentary excerpt from "Pitfalls to Avoid for a Strong Oncology Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls"
STUDY OVERVIEW
For a new oncology product to successfully enter the marketplace, organizations have to be vigilant of the many pitfalls that are part of the launch landscape... (ID 5159)
Companies Profiled: Abbott Laboratories, Amgen, Actelion, AstraZeneca, more ...
Price: $1862.00 Free Excerpt Available
| |
|
| | Pitfalls to Avoid for a Strong Metabolic Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls
|
Non-members: Click here to review a complimentary excerpt from "Pitfalls to Avoid for a Strong Metabolic Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls"
STUDY OVERVIEW
For a new metabolic product to successfully enter the marketplace, organizations have to be vigilant of the many pitfalls that are part of the launch landscape... (ID 5141)
Companies Profiled: Abbott Laboratories, Amgen, Actelion, AstraZeneca, more ...
Price: $1960.00 Free Excerpt Available
| |
|
| | Pitfalls to Avoid for a Strong Cardiovascular Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls
|
Non-members: Click here to review a complimentary excerpt from "Pitfalls to Avoid for a Strong Cardiovascular Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls"
STUDY OVERVIEW
For a new cardiovascular product to successfully enter the marketplace, organizations have to be vigilant of the many pitfalls that are part of the launch landscape... (ID 5132)
Companies Profiled: Abbott Laboratories, Amgen, Actelion, AstraZeneca, more ...
Price: $1960.00 Free Excerpt Available
| |
|
|